和黄医药2024年业绩滑坡:营收、净收益暴跌,肿瘤产品能否持续扛大旗?

21世纪经济报道
20 Mar

21世纪经济报道记者韩利明上海报道  3月19日晚间,和黄医药(0013.HK)公布2024年年度业绩显示,报告期内实现综合收入6.302亿美元,对比2023年度8.38亿美元的收入,同比下滑24.8%;同期,应占净收益为3770万美元,而2023年则为1.008亿美元,同比下降约62%。  在综合收入和净收益双降之际,其肿瘤药物的市场表现依旧强劲。2024年,肿瘤产品市场销售额增长134%,达到...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10